INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro

Inmune Bio Inc. and Quantum Computing Inc. (QCi) have announced a partnership to explore the potential of quantum computing and artificial intelligence (AI) in advancing Alzheimer's disease research and discovering new applications for INmune Bio's investigational treatment, XPro (XPro1595). The collaboration aims to apply quantum optimization, AI, and data analytics to identify new potential uses for XPro and prioritize indications with the highest success potential.

INmune Bio's pre-clinical research and clinical trial data, combined with QCi's Dirac-3S quantum optimization machine, will be utilized to analyze patient populations, biomarkers, and disease biology in a bid to uncover relationships that could lead to the identification of diseases driven by the same biology XPro targets. The companies also intend to prioritize diseases with the greatest potential for success, focusing on rare diseases that could benefit from smaller, faster, and more capital-efficient trials and potential pediatric approvals that may result in Priority Review Vouchers.

As part of the partnership, QCi will employ its quantum optimization machine alongside AI and conventional data analytics to delve into historical clinical data and biomedical datasets to find patterns and relationships that could help researchers better understand treatment responses, identify promising patient populations, and prioritize new indications for further study.

The collaboration will also see the companies compare results from QCi's quantum optimization machine with traditional statistical and machine-learning methods to determine the most effective approaches for different aspects of the analysis.

For INmune Bio, the collaboration offers a novel approach to evaluating the broader potential of XPro and identifying future development opportunities. For QCi, it represents an opportunity to demonstrate the practical applications of its low-power, room-temperature quantum computing technology in complex real-world problems, such as pharmaceutical research. The collaboration marks QCi's first commercial customer in the pharmaceutical and biotechnology market.